- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00773136
Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
March 20, 2014 updated by: Sara T. Wester, University of Miami
Effect of Bimatoprost (Lumigan) in Gel Suspension Applied to the Eyelashes on Eyelash Growth
Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes.
Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened and those who met inclusion criteria were enrolled.
Each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with GonakTM gel and labeled "right eye" and "left eye" according to randomization.
The suspension was applied to the eyelashes every evening on the designated eye for 6 weeks.
Lash length was measured with a caliper at enrollment, at weekly intervals during the study and at 1 and 3 months after study completion.
Visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals.
Results: The average eyelash growth in the Lumigan group was 2.01mm (vs.
control average of 1.13mm) which was a statistically significant difference (p=0.009).
The average intraocular pressure decreased equally in both groups (2.14 mmHg).
No change in visual acuity or iris discoloration was noted in any of the subjects.
Discussion: Our data showed an increase in eyelash length with use of Lumigan in gel suspension, suggesting that it may have eyelash lengthening properties.
Study Overview
Detailed Description
Study completed
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami, Bascom Palmer Eye Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age greater than 20 and less than 90 and patients who have previously used and are comfortable with applying mascara.
Exclusion Criteria:
- History of glaucoma, uveitis, pregnancy, allergic reaction to prostaglandins or the gel suspension, alopecia, and previous usage of other eyelash growth enhancement.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Bimatoprost Suspension
Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline.
They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left).
The intervention was the one eye with the Bimatoprost.
|
see prior
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of Bimatoprost in Lengthening of Eyelashes
Time Frame: 4.5 months (6 weeks of drug application and 3 months after discontinuing)
|
Eyelash growth after application of bimatoprost vs control (split face study).
|
4.5 months (6 weeks of drug application and 3 months after discontinuing)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (ACTUAL)
July 1, 2008
Study Completion (ACTUAL)
July 1, 2008
Study Registration Dates
First Submitted
October 15, 2008
First Submitted That Met QC Criteria
October 15, 2008
First Posted (ESTIMATE)
October 16, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
April 16, 2014
Last Update Submitted That Met QC Criteria
March 20, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20070706
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrichosis
-
Alexander ShayestehRecruitingHypertrichosis | Hirsutism - HypertrichosisSweden
-
Cutera Inc.Completed
-
Cutera Inc.WithdrawnHypertrichosisCanada
-
University of California, IrvineCompletedHypertrichosisUnited States
-
Derming SRLCompleted
-
Syneron MedicalUnknownExcess Hair GrowthUnited States
-
University of JenaUnknown
-
Follicum ABCompletedAlopecia | Hirsutism | HypertrichosisGermany
-
Scilex Ltd.UnknownHirsutism | Rhytides | Hypertrichosis | TelangiectasesIsrael
Clinical Trials on Bimatoprost Suspension
-
AllerganCompletedAlopecia | Alopecia, Androgenetic | BaldnessUnited States
-
AllerganCompletedAlopecia | Alopecia, Androgenetic | BaldnessUnited States
-
AllerganCompletedOcular Hypertension | Open-Angle GlaucomaUnited States, Israel, Canada, Singapore, Philippines, Spain, Australia, Belgium, Brazil, Germany
-
AllerganCompletedIdiopathic Eyelash HypotrichosisRussian Federation, Sweden, United States, United Kingdom
-
Kenneth BeerAllerganCompleted
-
AllerganCompleted
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedAndrogenetic AlopeciaUnited States